Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor.

Central core disease (CCD) is an autosomal dominant congenital myopathy. Diagnosis is based on the presence of cores in skeletal muscles. CCD has been linked to the gene encoding the ryanodine receptor (RYR1) and is considered to be an allelic disease of malignant hyperthermia susceptibility. However, the report of a recessive form of transmission together with a variable clinical presentation has raised the question of the genetic heterogeneity of the disease. Analyzing a panel of 34 families exclusively recruited on the basis of both clinically and morphologically expressed CCD, 12 different mutations of the C-terminal domain of RYR1 have been identified in 16 unrelated families. Morphological analysis of the patients' muscles showed different aspects of cores, all of them associated with mutations in the C-terminal region of RYR1. Furthermore, we characterized the presence of neomutations in the RyR1 gene in four families. This indicates that neomutations into the RyR1 gene are not a rare event and must be taken into account for genetic studies of families that present with congenital myopathies type 'central core disease'. Three mutations led to the deletion in frame of amino acids. This is the first report of amino acid deletions in RYR1 associated with CCD. According to a four-transmembrane domain model, the mutations concentrated mostly in the myoplasmic and luminal loops linking, respectively, transmembrane domains T1 and T2 or T3 and T4 of RYR1.

[1]  B. Britt,et al.  A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. , 1991, Genomics.

[2]  G. Shy,et al.  A new congenital non-progressive myopathy. , 1956, Brain : a journal of neurology.

[3]  T. Nelson,et al.  Single-amino-acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. , 2001, American journal of human genetics.

[4]  V. Sorrentino,et al.  Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families , 1999, Journal of medical genetics.

[5]  N. Romero,et al.  Malignant hyperthermia and central core disease: Analysis of two families with heterogeneous clinical expression , 1993, Neuromuscular Disorders.

[6]  T. McCarthy,et al.  Ryanodine receptor mutations in malignant hyperthermia and central core disease , 2000, Human mutation.

[7]  A. Shuaib,et al.  Central Core Disease: CLINICAL FEATURES IN 13 PATIENTS , 1987, Medicine.

[8]  L. Xu,et al.  Evidence for a role of the lumenal M3-M4 loop in skeletal muscle Ca(2+) release channel (ryanodine receptor) activity and conductance. , 2000, Biophysical journal.

[9]  L Zhang,et al.  Molecular Identification of the Ryanodine Receptor Pore-forming Segment* , 1999, The Journal of Biological Chemistry.

[10]  P. Hopkins Malignant hyperthermia: advances in clinical management and diagnosis. , 2000, British journal of anaesthesia.

[11]  C. Doriguzzi,et al.  Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia , 1993, Nature Genetics.

[12]  M. Phillips,et al.  The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. , 1996, Genomics.

[13]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[14]  M. Phillips,et al.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia , 1990, Nature.

[15]  F. Ellis European Malignant Hyperpyrexia Group. , 1984, British journal of anaesthesia.

[16]  F. Lehmann-Horn,et al.  Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. , 1999, Human molecular genetics.

[17]  G. Comi,et al.  Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. , 1998, American journal of human genetics.

[18]  L. Bridges,et al.  Segregation of malignant hyperthermia, central core disease and chromosome 19 markers. , 1999, British journal of anaesthesia.

[19]  E. Hoffman,et al.  A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy , 2000, Neurology.

[20]  T. Noda,et al.  Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene , 1994, Nature.

[21]  N. Monnier,et al.  Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. , 1994, Genomics.

[22]  M. Jeanpierre A rapid method for the purification of DNA from blood. , 1987, Nucleic acids research.

[23]  T. Nelson,et al.  Central core disease and malignant hyperthermia syndrome , 1980 .

[24]  D. Maclennan,et al.  Functional Consequences of Mutations of Conserved, Polar Amino Acids in Transmembrane Sequences of the Ca2+ Release Channel (Ryanodine Receptor) of Rabbit Skeletal Muscle Sarcoplasmic Reticulum* , 1998, The Journal of Biological Chemistry.

[25]  N. Romero,et al.  An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. , 2000, Human molecular genetics.

[26]  H. Takeshima,et al.  Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor , 1989, Nature.

[27]  A. Toutain,et al.  Multi‐minicore disease–searching for boundaries: Phenotype analysis of 38 cases , 2000, Annals of neurology.

[28]  M. Farrall,et al.  Localization of the malignant hyperthermia susceptibility locus to human chromosome 19ql2–13.2 , 1990, Nature.

[29]  G. Ávila,et al.  Excitation–contraction uncoupling by a human central core disease mutation in the ryanodine receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Dalakas,et al.  Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P Stieglitz,et al.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. , 1997, American journal of human genetics.

[32]  M. Lehane,et al.  A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Phillips,et al.  Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. , 1990, The Journal of biological chemistry.

[34]  K. Stowell,et al.  A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. , 2000, Human molecular genetics.

[35]  F. Muntoni,et al.  A severe clinical and pathological variant of central core disease with possible autosomal recessive inheritance , 1998, Neuromuscular Disorders.

[36]  M. Phillips,et al.  A mutation in the human ryanodine receptor gene associated with central core disease , 1993, Nature Genetics.

[37]  D. Maclennan,et al.  Measurement of Resting Cytosolic Ca2+ Concentrations and Ca2+ Store Size in HEK-293 Cells Transfected with Malignant Hyperthermia or Central Core Disease Mutant Ca2+ Release Channels* , 1999, The Journal of Biological Chemistry.

[38]  S. Grinstein,et al.  Caffeine and Halothane Sensitivity of Intracellular Ca2+ Release Is Altered by 15 Calcium Release Channel (Ryanodine Receptor) Mutations Associated with Malignant Hyperthermia and/or Central Core Disease* , 1997, The Journal of Biological Chemistry.

[39]  G. Meissner,et al.  Luminal loop of the ryanodine receptor: a pore-forming segment? , 1999, Proceedings of the National Academy of Sciences of the United States of America.